KALV
KalVista Pharmaceuticals, Inc.Company Information
- Company Name
- KalVista Pharmaceuticals, Inc.
- CIK
- CIK0001348911
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- KALV: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KALV
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-04-09
- Last sale
- 2026-05-27
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 321,448
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 68,891,970
- Shares outstanding
- 54,583,424
- Ownership
- 126.21%
Earnings Market Reaction
- Filing date
- 2026-05-14
- Price on filing date
- —
- 1-month reaction
- 0.71%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-09-30 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | 2023-07-31 | 2023-04-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 214 | 243 | 124 | 132 | 167 | 42 | 32 | 32 | 23 | 58 | 49 | 56 | ||||||
| Available For Sale Securities Debt Securities Current | 71 | 66 | 67 | 89 | 86 | 94 | 142 | 179 | 53 | 46 | 74 | 93 | ||||||
| Receivables Net Current | 10 | 6 | 2 | - | - | - | - | - | - | - | - | - | ||||||
| Inventory Net | 4 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 8 | 8 | 12 | 20 | 7 | 5 | 7 | 7 | 6 | 5 | 8 | 6 | ||||||
| Assets Current | 314 | 325 | 206 | 242 | 267 | 152 | 192 | 226 | 104 | 129 | 150 | 172 | ||||||
| Property Plant And Equipment Net | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | ||||||
| Operating Lease Right Of Use Asset | 9 | 9 | 5 | 6 | 5 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | ||||||
| Other Assets Noncurrent | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Assets | 329 | 340 | 216 | 251 | 276 | 161 | 200 | 235 | 114 | 139 | 160 | 183 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 8 | 8 | 6 | 5 | 6 | 5 | 11 | 9 | 3 | 5 | 5 | 5 | ||||||
| Accrued Liabilities Current | 34 | 21 | 19 | 27 | 18 | 15 | 10 | 12 | 15 | 12 | 8 | 9 | ||||||
| Contract With Customer Liability Current | 1 | 12 | 11 | 11 | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 2 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 61 | 45 | 38 | 45 | 26 | 22 | 22 | 23 | 19 | 18 | 14 | 15 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Deferred Revenue Noncurrent | 21 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 10 | 9 | 4 | 4 | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | ||||||
| Liabilities Noncurrent | - | - | 136 | 110 | 105 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | ||||||
| Convertible Debt Noncurrent | 139 | 139 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 349 | 323 | - | - | - | - | - | - | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 774 | 763 | 760 | 754 | 748 | 689 | 686 | 680 | 517 | 514 | 511 | 507 | ||||||
| Retained Earnings Accumulated Deficit | -786 | -739 | -713 | -653 | -601 | -552 | -510 | -470 | -425 | -396 | -368 | -343 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -7 | -7 | -6 | -5 | -2 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | ||||||
| Stockholders Equity | -20 | 17 | 41 | 95 | 145 | 149 | 173 | 207 | 89 | 114 | 139 | 161 | ||||||
| Liabilities And Stockholders Equity | 329 | 340 | 216 | 251 | 276 | 161 | 200 | 235 | 114 | 139 | 160 | 183 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | - | - | 5 | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 51 | 51 | 50 | 50 | 49 | 43 | 43 | 43 | 35 | 34 | 34 | 34 | ||||||
| Shares Outstanding | 51 | 51 | 50 | 50 | 49 | 43 | 43 | 43 | 35 | 34 | 34 | 34 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKalVista Pharmaceuticals, Inc. (KALV) — SEC Financial Statements & Analysis
KalVista Pharmaceuticals, Inc. (KALV) is a pharmaceutical preparations company, incorporated in DE. KalVista Pharmaceuticals, Inc. trades on Nasdaq as: KALV. KalVista Pharmaceuticals, Inc. (KALV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-14. Based on that filing, On profitability, KalVista Pharmaceuticals, Inc. posts an operating margin of -332.01%, a net margin of -336.67%, a Return on Equity (ROE) of -300.42%, a Return on Assets (ROA) of -62.31%, and a Return on Invested Capital (ROIC) of -206.81%. Per share, it reports EPS of $-3.45, diluted EPS of $-3.45, free cash flow per share of $-3.11, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 9.14% year-over-year and EPS growth of 5.25% year-over-year. On the balance sheet, it maintains a current ratio of 5.17x, a quick ratio of 4.97x, working capital of $253.39M, a debt-to-equity ratio of -17.74x, a debt ratio of 1.06, an interest coverage ratio of -13.41x, free cash flow of $-169.49M (TTM), and net debt of $-74.37M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-3.45
- ROE TTM
- -300.42%
- ROA TTM
- -62.31%
- Debt To Equity
- -17.74x
- Free Cash Flow TTM
- $-169.49M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is KalVista Pharmaceuticals, Inc. in?
KalVista Pharmaceuticals, Inc. (KALV) operates in the Pharmaceutical Preparations industry.
What exchange does KALV trade on?
KalVista Pharmaceuticals, Inc. (KALV) trades on the Nasdaq.
Where is KalVista Pharmaceuticals, Inc. incorporated?
KalVista Pharmaceuticals, Inc. is incorporated in DE.
When was KalVista Pharmaceuticals, Inc. (KALV)'s most recent SEC filing?
KalVista Pharmaceuticals, Inc. (KALV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-14.
What is KALV's EPS (earnings per share)?
KalVista Pharmaceuticals, Inc. (KALV)'s trailing twelve month EPS is $-3.45 as of 2026-03-31.
What is KALV's ROE (return on equity)?
KalVista Pharmaceuticals, Inc. (KALV)'s trailing twelve month Return on Equity (ROE) is -300.42% as of 2026-03-31.
What is KALV's ROA (return on assets)?
KalVista Pharmaceuticals, Inc. (KALV)'s trailing twelve month Return on Assets (ROA) is -62.31% as of 2026-03-31.
What is KALV's ROIC (return on invested capital)?
KalVista Pharmaceuticals, Inc. (KALV)'s trailing twelve month Return on Invested Capital (ROIC) is -206.81% as of 2024-10-31.